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Background: There were no published data regarding the clinical efficacy and safety of new drug-eluting stent (everolimus-eluting stent, EES) 
following primary percutaneous coronary intervention (PPCI) in ST-elevation myocardial infarction (STEMI). We evaluated the one-year outcome of 
everolimus-eluting stent versus to 1st generation (sirolimus-eluting stent, SES and paclitaxel-eluting stent, PES) and 2nd generation (zotarolimus-
eluting stent) drug-eluting stents(DES) for the treatment of STEMI.
Methods: A prospective, open-labeled, multi-center cohort has been performed at 4 centers in Korea. All patients will be clinically followed-up for 
two years. The primary endpoint was major adverse cardiac event (MACE): the composite of cardiac death (CD), recurrent MI and ischemia-driven 
target vessel revascularization (TVR) at 1 year. Stent thromboses (ST) by ARC definition were analyzed.
Results: Total 797 patients (EES=197, ZES=203, SES=203, PES=194) who were completed more than one year were analyzed. One-year MACE were 
2.0%, 5.9%, 3.4% and 5.7% in EES-, ZES-, SES- and PES-group, respectively (p=ns). Cardiac death was 1.0%, 2.5%, 1.5% and 1.0% in EES-, ZES-, 
SES- and PES-group, respectively (p=ns). ST was 0%, 2.0%, 2.0% and 2.0% in EES-, ZES-, SES- and PES- group, respectively (p=ns).
Conclusions: Campared to 1st and 2nd generation DES (SES and PES, ZES), EES showed similar one-year clinical outcomes in terms of MACE in 
patients with STEMI following pPCI and no stent thrombosis.
Clinical events at 12 months and stent thrombosis
EES (n=197) ZES (n=203) SES (n=203) PES (n=194) P Value
MACE, N (%) 6 (3.1) 12 (5.9) 7 (3.4) 11 (5.7) 0.322
Cardiac death, N (%) 2 (1.0) 5 (2.5) 3 (1.5) 2 (1.0) 0.646
Recurrent MI, N (%) 1 (0.5) 2 (1.0) 4 (2.0) 6 (3.1) 0.781
Ischemia-driven TLR, N (%) 3 (1.5) 5 (2.5) 0 3 (1.5) 0.190
Stent thrombosis, N (%) 0 4 (2.0) 4 (2.0) 4 (2.0) 0.719
